Login to Your Account

Pacific pride: Abraxis veteran grooms dormant Celgene drug for success

By Michael Fitzhugh
Staff Writer

Tuesday, May 20, 2014

Aadi LLC, a small new biotech company led by Abraxane (nab-paclitaxel) co-inventor Neil Desai, is in-licensing a once-shelved nanoparticle therapy from Celgene Corp. to develop it for oncology and cardiovascular indications. Celgene acquired the drug, ABI-009, in its 2010 acquisition of Abraxis Bioscience Inc. and retains an option to reacquire it in the new deal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription